首页> 美国卫生研究院文献>other >Decreased non-specific Adhesivity Receptor Targeted (DART) nanoparticles exhibit improved dispersion cellular uptake and tumor retention in invasive gliomas
【2h】

Decreased non-specific Adhesivity Receptor Targeted (DART) nanoparticles exhibit improved dispersion cellular uptake and tumor retention in invasive gliomas

机译:降低的非特异性粘附力靶向受体(DART)纳米颗粒在浸润性神经胶质瘤中表现出改善的分散性细胞摄取和肿瘤保留

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The most common and deadly form of primary brain cancer, glioblastoma (GBM), is characterized by significant intratumoral heterogeneity, microvascular proliferation, immune system suppression, and brain tissue invasion. Delivering effective and sustained treatments to the invasive GBM cells intermixed with functioning neural elements is a major goal of advanced therapeutic systems for brain cancer. Previously, we investigated the nanoparticle characteristics that enable targeting of invasive GBM cells. This revealed the importance of minimizing non-specific binding within the relatively adhesive, ‘sticky’ microenvironment of the brain and brain tumors in particular. We refer to such nanoformulations with decreased non-specific adhesivity and receptor targeting as ‘DART’ therapeutics. In this work, we applied this information towards the design and characterization of biodegradable nanocarriers, and in vivo testing in orthotopic experimental gliomas. We formulated particulate nanocarriers using poly(lactic-co-glycolic acid) (PLGA) and PLGA-polyethylene glycol (PLGA-PEG) polymers to generate sub-100 nm nanoparticles with minimal binding to extracellular brain components and strong binding to the Fn14 receptor – an upregulated, conserved component in invasive GBM. Multiple particle tracking in brain tissue slices and in vivo testing in orthotopic murine malignant glioma revealed preserved nanoparticle diffusivity and increased uptake in brain tumor cells. These combined characteristics also resulted in longer retention of the DART nanoparticles within the orthotopic tumors compared to non-targeted versions. Taken together, these results and nanoparticle design considerations offer promising new methods to optimize therapeutic nanocarriers for improving drug delivery and treatment for invasive brain tumors.
机译:原发性脑癌最常见和致命的形式是胶质母细胞瘤(GBM),其特征是明显的肿瘤内异质性,微血管增生,免疫系统抑制和脑组织浸润。对与功能性神经元混合在一起的侵入性GBM细胞进行有效和持续的治疗,是先进的脑癌治疗系统的主要目标。以前,我们研究了能够靶向侵入性GBM细胞的纳米颗粒特征。这揭示了最小化相对粘着的,尤其是大脑和大脑肿瘤的“粘性”微环境内的非特异性结合的重要性。我们将这种具有非特异性粘附力和受体靶向性降低的纳米制剂称为“ DART”疗法。在这项工作中,我们将此信息应用于可生物降解的纳米载体的设计和表征,以及在原位实验神经胶质瘤中的体内测试。我们使用聚乳酸-乙醇酸(PLGA)和PLGA-聚乙二醇(PLGA-PEG)聚合物配制了微粒纳米载体,以生成100 nm以下的纳米颗粒,其与细胞外脑成分的结合最少,与Fn14受体的结合力强–侵入性GBM中上调的保守成分。在脑组织切片中进行多个颗粒追踪,以及在原位鼠恶性神经胶质瘤中进行体内测试,发现纳米颗粒的扩散性得以保留,并且在脑肿瘤细胞中的摄取增加。与非靶向形式相比,这些组合特征还导致DART纳米粒子在原位肿瘤内的保留时间更长。综上所述,这些结果和纳米颗粒设计的考虑因素提供了有前途的新方法,可以优化治疗性纳米载体,从而改善药物输送和侵袭性脑肿瘤的治疗。

著录项

相似文献

  • 外文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号